Sotac Pharmaceuticals Limited

Sotac Pharmaceuticals Dividend

Sotac Pharmaceuticals Limited has announced a record date of September 23, 2026, for the payment of a final dividend of Rs. 0.20 per share.

Sotac Pharmaceuticals Annual General Meeting

Sotac Pharmaceuticals Limited issued the notice for its 11th Annual General Meeting on September 30, 2026. Ordinary and special business will be transacted.

Sotac Pharmaceuticals Board Meeting Outcome

Sotac Pharmaceuticals' board approved the 11th AGM for September 30, 2026, and recommended a dividend of Rs. 0.20 per share.

Sotac Pharmaceuticals Bags ₹0.98 Cr Order

Sotac Pharmaceuticals received a purchase order from Intas Pharmaceuticals Limited for finished pharmaceutical formulations. The order is valued at ₹0.98 Crore.

Value

₹0.98 Cr

Execution

September 05, 2026 to November 05, 2026

Sotac Pharmaceuticals Dividend

Sotac Pharmaceuticals recommended a final dividend of ₹0.20 per equity share for FY 2025-26. The distribution awaits shareholder approval at the upcoming AGM.

Sotac Pharmaceuticals H2 FY26 Results: Net Profit ₹3.3 Cr, Down 45.9% YoY

Sotac Pharmaceuticals Limited reported revenue from operations of ₹60.1 Cr (+27.6% YoY) and net profit of ₹3.3 Cr (-45.9% YoY) for H2 FY26.

Key figure

Net profit ₹3.3 Cr · -45.9% YoY

Sotac Pharmaceuticals Financial Results

Sotac Pharmaceuticals reported audited FY26 results and proposed a Rs. 0.20 per share dividend. Consolidated annual revenue reached ₹101.24 Crore with a net profit of ₹5.77 Crore.

Value

₹0.22 Cr

Sotac Pharmaceuticals Other Announcement

Sotac Pharmaceuticals Limited submitted its annual SDD Compliance Certificate for the year ended March 31, 2026. The filing confirms regulatory compliance under PIT Regulations.

Sotac Pharmaceuticals Board Meeting Date

Sotac Pharmaceuticals scheduled a board meeting for May 26, 2026. The board will consider audited financial results and a final dividend for fiscal 2026.

Sotac Pharmaceuticals Other Announcement

Sotac Pharmaceuticals Limited informed the NSE that it is exempt from filing quarterly Corporate Governance Reports under SEBI Regulation 27(2). The exemption applies because the company's equity shares are listed on the NSE SME Emerge Platform, meeting the non-applicability criteria under Regulation 15(2)(b).